Capital-infusions

Capital-infusions is a retail forex and CFD broker registered in the United States, with a stated founding date of August 7, 2024. The company lists its official registered address as 2177 5th Ave #APT 3b, New York, NY 10037. It offers online trading services across multiple asset classes, including over 50 currency pairs, shares, indices, commodities, and cryptocurrencies.

As a relatively new entrant to the brokerage industry, Capital-infusions presents itself as a multi-asset trading platform catering to both novice and experienced traders. However, publicly available independent information about the broker's operations, ownership, and track record is extremely limited at this time.

According to our records, Capital-infusions holds no known regulatory licences from any financial oversight authority. This is a critical factor for traders to consider, as the absence of regulation means there is no external body monitoring the broker's conduct, segregation of client funds, or adherence to financial standards.

FXCanary's proprietary Scam Risk Score for Capital-infusions is 51 out of 100, indicating an elevated level of risk. The lack of regulatory oversight is a primary contributor to this assessment. Traders should exercise caution and perform thorough due diligence before engaging with this broker.

Capital-infusions offers two account types: the GO Plus + and the Standard account. Both accounts require a minimum deposit of A$200 (approximately $130 USD as of late 2024). The broker provides a maximum leverage of 1:500 on both account tiers, which is considered very high and carries significant risk.

While specific details on spreads, commissions, and additional features are not available from public records, the uniform minimum deposit and leverage suggest that the broker targets traders seeking access to high-leverage trading with a relatively low entry barrier. The lack of account differentiation may imply limited customisation for different trading strategies.

The broker claims to offer a diverse range of trading instruments, including over 50 forex pairs, shares, indices, commodities, and cryptocurrencies. This selection is typical for multi-asset brokers and positions Capital-infusions to attract traders interested in diversifying their portfolios across different asset classes.

However, without independent verification or access to the broker's trading platform, it is not possible to confirm the actual breadth of instruments available or the quality of execution. Prospective traders should be aware that listed instruments can differ from what is actually tradable in a live account.

The minimum deposit of A$200 is relatively low, making the broker accessible to retail traders with limited capital. The maximum leverage of 1:500 is among the highest in the industry, amplifying both potential gains and potential losses dramatically. Such high leverage is often associated with increased risk of margin calls and rapid account depletion.

As the broker is unregulated, there are no mandated leverage limits or investor compensation schemes in place. Traders considering Capital-infusions should carefully evaluate their risk tolerance and ensure they understand the implications of trading with such high leverage.

Capital-infusions appears to target retail traders from various regions, as the minimum deposit is quoted in Australian dollars, suggesting a potential focus on the Asia-Pacific market despite its US registration. The low entry barrier and high leverage are typical selling points for beginners or traders with small accounts seeking quick returns.

That said, the lack of regulatory oversight and the elevated risk score from FXCanary indicate that this broker may not be suitable for risk-averse or long-term investors. Experienced traders who accept higher risk may find the offering worth investigating, but only after thorough independent research.